Works matching IS 01676997 AND DT 2012 AND VI 30 AND IP 3

Results: 56

Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group)

Published in:

2012

By:

Schultheis, Beate;
Strumberg, Dirk;
Bergmann, Lothar;
Graeven, Ullrich;
Hanauske, Axel-Rainer;
Lipp, Rainer;
Schuette, Jochen;
Saito, K.;
Scigalla, Paul;
Scheulen, Max

Publication type:

Journal Article

Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.

Published in:

2012

By:

Okamoto, Isamu;
Yamamoto, Nobuyuki;
Kubota, Kaoru;
Ohe, Yuichiro;
Nogami, Naoyuki;
Murakami, Haruyasu;
Yamaya, Hidetoshi;
Ono, Katsuhiro;
Nakagawa, Kazuhiko

Publication type:

Journal Article

Inhibition of TGF-[beta] signaling, vasculogenic mimicry and proinflammatory gene expression by isoxanthohumol.

Published in:

2012

By:

Serwe, Annegret;
Rudolph, Kristina;
Anke, Timm;
Erkel, Gerhard

Publication type:

Journal Article

Further developments for improving response and tolerance to irradiation for advanced renal cancer: concurrent (mTOR) inhibitor RAD001 and helical tomotherapy.

Published in:

2012

By:

Kirova, Youlia;
Servois, Vincent;
Chargari, Cyrus;
Amessis, Malika;
Zerbib, Marc;
Beuzeboc, Philippe

Publication type:

Report

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1138, doi. 10.1007/s10637-010-9619-8

By:

Strumberg, Dirk;
Schultheis, Beate;
Scheulen, M.;
Hilger, R.;
Krauss, J.;
Marschner, N.;
Lordick, F.;
Bach, F.;
Reuter, D.;
Edler, L.;
Mross, K.

Publication type:

Article

Everolimus-related organizing pneumonia: a report establishing causality.

Published in:

2012

By:

Frija, Justine;
Joly, Dominique;
Knebelmann, Bertrand;
Dusser, Daniel;
Burgel, Pierre-Régis

Publication type:

Report

TRAIL shows potential cardioprotective activity.

Published in:

2012

By:

Toffoli, Barbara;
Bernardi, Stella;
Candido, Riccardo;
Zacchigna, Serena;
Fabris, Bruno;
Secchiero, Paola

Publication type:

Report

Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 853, doi. 10.1007/s10637-010-9622-0

By:

Maliakal, Pius;
Abdelrahim, Maen;
Sankpal, Umesh;
Maliakal, Cima;
Baker, Cheryl;
Safe, Stephen;
Herrera, Luis;
Abudayyeh, Ala;
Kaja, Sumanth;
Basha, Riyaz

Publication type:

Article

Caspase-independent apoptosis induction of quorum-sensing autoinducer analogs against chronic myeloid leukemia K562.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 862, doi. 10.1007/s10637-010-9623-z

By:

Hazawa, Masaharu;
Kudo, Michiko;
Iwata, Toshihiro;
Saito, Kazuki;
Takahashi, Kenji;
Igarashi, Jun;
Suga, Hiroaki;
Kashiwakura, Ikuo

Publication type:

Article

Antimetastatic activity and low systemic toxicity of tetradecyl gallate in a preclinical melanoma mouse model.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 870, doi. 10.1007/s10637-010-9628-7

By:

Locatelli, Claudriana;
Carvalho, Deborah;
Mascarello, Alessandra;
Cordova, Clarissa;
Yunes, Rosendo;
Nunes, Ricardo;
Pilati, Celso;
Creczynski-Pasa, Tânia

Publication type:

Article

Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.

Published in:

2012

By:

Davidson, David;
Coulombe, Yannick;
Martinez-Marignac, Veronica;
Amrein, Lilian;
Grenier, Jeremy;
Hodkinson, Keira;
Masson, Jean-Yves;
Aloyz, Raquel;
Panasci, Lawrence

Publication type:

Report

Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1039, doi. 10.1007/s10637-010-9629-6

By:

Tevaarwerk, Amye;
Wilding, George;
Eickhoff, Jens;
Chappell, Rick;
Sidor, Carolyn;
Arnott, Jamie;
Bailey, Howard;
Schelman, William;
Liu, Glenn

Publication type:

Article

A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1144, doi. 10.1007/s10637-011-9631-7

By:

Zhao, Xin;
Mei, Kai;
Cai, Xiaohong;
Chen, Jing;
Yu, Jingrui;
Zhou, Chengya;
Li, Qiu

Publication type:

Article

Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1046, doi. 10.1007/s10637-010-9630-0

By:

Niwakawa, Masashi;
Hashine, Katsuyoshi;
Yamaguchi, Raizo;
Fujii, Hirofumi;
Hamamoto, Yasuo;
Fukino, Koichi;
Tanigawa, Takahiko;
Sumiyoshi, Yoshiteru

Publication type:

Article

Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1150, doi. 10.1007/s10637-011-9634-4

By:

Lee, Soohyeon;
Yoon, Sang;
Park, Jun;
Kim, Do;
Ahn, Sang;
Han, Kwang-Hyub;
Choi, Hye

Publication type:

Article

A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 880, doi. 10.1007/s10637-011-9636-2

By:

Castro, Jessica;
Ribó, Marc;
Puig, Teresa;
Colomer, Ramon;
Vilanova, Maria;
Benito, Antoni

Publication type:

Article

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1055, doi. 10.1007/s10637-011-9637-1

By:

Fujiwara, Yutaka;
Kiyota, Naomi;
Chayahara, Naoko;
Suzuki, Akiyuki;
Umeyama, Yoshiko;
Mukohara, Toru;
Minami, Hironobu

Publication type:

Article

Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1065, doi. 10.1007/s10637-011-9642-4

By:

Millward, Michael;
Mainwaring, Paul;
Mita, Alain;
Federico, Kristine;
Lloyd, G.;
Reddinger, Natasha;
Nawrocki, Steffan;
Mita, Monica;
Spear, Matthew

Publication type:

Article

In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 889, doi. 10.1007/s10637-011-9641-5

By:

Liu, Xiangrui;
Lam, Frankie;
Shi, Shenhua;
Fischer, Peter;
Wang, Shudong

Publication type:

Article

Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1074, doi. 10.1007/s10637-011-9639-z

By:

O'Day, Steven;
Pavlick, Anna;
Albertini, Mark;
Hamid, Omid;
Schalch, Heidi;
Lang, Zhihui;
Ling, Jie;
Mata, Marielena;
Reddy, Manjula;
Foster, Brenda

Publication type:

Article

Inhibition of TGF-β signaling, vasculogenic mimicry and proinflammatory gene expression by isoxanthohumol.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 898, doi. 10.1007/s10637-011-9643-3

By:

Serwe, Annegret;
Rudolph, Kristina;
Anke, Timm;
Erkel, Gerhard

Publication type:

Article

Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 916, doi. 10.1007/s10637-011-9645-1

By:

Onimoe, Grace-Ifeyinwa;
Liu, Aiguo;
Lin, Li;
Wei, Chang-Ching;
Schwartz, Eric;
Bhasin, Deepak;
Li, Chenglong;
Fuchs, James;
Li, Pui-kai;
Houghton, Peter;
Termuhlen, Amanda;
Gross, Thomas;
Lin, Jiayuh

Publication type:

Article

Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1261, doi. 10.1007/s10637-011-9644-2

By:

Santos, Edgardo;
Gomez, Jorge;
Raez, Luis

Publication type:

Article

Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1224, doi. 10.1007/s10637-011-9648-y

By:

Shitara, Kohei;
Ikeda, Junko;
Yokota, Tomoya;
Takahari, Daisuke;
Ura, Takashi;
Muro, Kei;
Matsuo, Keitaro

Publication type:

Article

Hepatic arterial infusion (HAI) with PEGylated liposomes containing 5-FU improves tumor control of liver metastases in a rat model.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 927, doi. 10.1007/s10637-011-9646-0

By:

Pohlen, Uwe;
Buhr, Heinz;
Berger, Gerd;
Ritz, Jörg-Peter;
Holmer, Christoph

Publication type:

Article

Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 936, doi. 10.1007/s10637-011-9640-6

By:

Burkholder, Timothy;
Clayton, Joshua;
Rempala, Mark;
Henry, James;
Knobeloch, John;
Mendel, David;
McLean, Johnathan;
Hao, Yan;
Barda, David;
Considine, Eileen;
Uhlik, Mark;
Chen, Yuefeng;
Ma, Liandong;
Bloem, Laura;
Akunda, Jacqueline;
McCann, Denis;
Sanchez-Felix, Manuel;
Clawson, David;
Lahn, Michael;
Starling, James

Publication type:

Article

DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1- c][1,4]benzodiazepine dimer SG2057.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 950, doi. 10.1007/s10637-011-9647-z

By:

Hartley, John;
Hamaguchi, Anzu;
Suggitt, Marie;
Gregson, Stephen;
Thurston, David;
Howard, Philip

Publication type:

Article

A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1158, doi. 10.1007/s10637-011-9650-4

By:

Mackay, Helen;
Au, Heather;
McWhirter, Elaine;
Alcindor, Thierry;
Jarvi, Andrea;
MacAlpine, Katrina;
Wang, Lisa;
Wright, John;
Oza, Amit

Publication type:

Article

A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1082, doi. 10.1007/s10637-011-9656-y

By:

Cabebe, Elwyn;
Fisher, George;
Sikic, Branimir

Publication type:

Article

A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1175, doi. 10.1007/s10637-011-9658-9

By:

El-Khoueiry, A.;
Ramanathan, R.;
Yang, D.;
Zhang, W.;
Shibata, S.;
Wright, J.;
Gandara, D.;
Lenz, H.

Publication type:

Article

Cell cycle arrest through inhibition of tubulin polymerization by withaphysalin F, a bioactive compound isolated from Acnistus arborescens.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 959, doi. 10.1007/s10637-011-9649-x

By:

Rocha, Danilo;
Balgi, Aruna;
Maia, Ana;
Pessoa, Otilia;
Silveira, Edilberto;
Costa-Lotufo, Letícia;
Roberge, Michel;
Pessoa, Claudia

Publication type:

Article

Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 967, doi. 10.1007/s10637-011-9655-z

By:

Goyeneche, Alicia;
Seidel, Erin;
Telleria, Carlos

Publication type:

Article

In vivo toxicity study of N-1-sulfonylcytosine derivatives and their mechanisms of action in cervical carcinoma cell line.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 981, doi. 10.1007/s10637-011-9657-x

By:

Kašnar-Šamprec, Jelena;
Ratkaj, Ivana;
Mišković, Katarina;
Pavlak, Marina;
Baus-Lončar, Mirela;
Kraljević Pavelić, Sandra;
Glavaš-Obrovac, Ljubica;
Žinić, Biserka

Publication type:

Article

A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1088, doi. 10.1007/s10637-011-9653-1

By:

Holen, Kyle;
DiPaola, Robert;
Liu, Glenn;
Tan, Antoinette;
Wilding, George;
Hsu, Karl;
Agrawal, Nancy;
Chen, Cong;
Xue, Lingling;
Rosenberg, Elizabeth;
Stein, Mark

Publication type:

Article

A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1164, doi. 10.1007/s10637-011-9651-3

By:

Oh, Do-Youn;
Lee, Keun;
Lee, Kyung-Hee;
Sohn, Chang-Hak;
Park, Young;
Zang, Dae;
Ryoo, Hun-Mo;
Song, Hong-Suk;
Kim, Jin-Soo;
Kang, Hye-Jin;
Kim, Bong-Seog;
Bang, Yung-Jue

Publication type:

Article

Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genes.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 991, doi. 10.1007/s10637-011-9654-0

By:

Otová, Berta;
Ojima, Iwao;
Václavíková, Radka;
Hrdý, Jiří;
Ehrlichová, Marie;
Souček, Pavel;
Vobořilová, Jana;
Němcová, Vlasta;
Zanardi, Ilaria;
Horský, Stanislav;
Kovář, Jan;
Gut, Ivan

Publication type:

Article

Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1107, doi. 10.1007/s10637-011-9660-2

By:

Kantarjian, H.;
Padmanabhan, S.;
Stock, W.;
Tallman, M.;
Curt, G.;
Li, J.;
Osmukhina, A.;
Wu, K.;
Huszar, D.;
Borthukar, G.;
Faderl, S.;
Garcia-Manero, G.;
Kadia, T.;
Sankhala, K.;
Odenike, O.;
Altman, J.;
Minden, M.

Publication type:

Article

Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group).

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1184, doi. 10.1007/s10637-011-9665-x

By:

Schultheis, Beate;
Strumberg, Dirk;
Bergmann, Lothar;
Graeven, Ullrich;
Hanauske, Axel-Rainer;
Lipp, Rainer;
Schuette, Jochen;
Saito, K.;
Scigalla, Paul;
Scheulen, Max

Publication type:

Article

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1096, doi. 10.1007/s10637-011-9666-9

By:

Fukutomi, Akira;
Hatake, Kiyohiko;
Matsui, Kaoru;
Sakajiri, Sakura;
Hirashima, Tomonori;
Tanii, Hiromi;
Kobayashi, Ken;
Yamamoto, Nobuyuki

Publication type:

Article

A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1193, doi. 10.1007/s10637-011-9662-0

By:

Cesne, Axel;
Yovine, Alejandro;
Blay, Jean-Yves;
Delaloge, Suzette;
Maki, Robert;
Misset, Jean-Louis;
Frontelo, Pilar;
Nieto, Antonio;
Jiao, Juhui;
Demetri, George

Publication type:

Article

A novel synthetic C-1 analogue of 7-deoxypancratistatin induces apoptosis in p53 positive and negative human colorectal cancer cells by targeting the mitochondria: enhancement of activity by tamoxifen.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1012, doi. 10.1007/s10637-011-9668-7

By:

Ma, Dennis;
Tremblay, Phillip;
Mahngar, Kevinjeet;
Akbari-Asl, Pardis;
Collins, Jonathan;
Hudlicky, Tomas;
McNulty, James;
Pandey, Siyaram

Publication type:

Article

Aminopyrimidoisoquinolinequinone (APIQ) redox cycling is potentiated by ascorbate and induces oxidative stress leading to necrotic-like cancer cell death.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1003, doi. 10.1007/s10637-011-9661-1

By:

Vásquez, David;
Verrax, Julien;
Valderrama, Jaime;
Calderon, Pedro

Publication type:

Article

Multifunctional 5-aminolevulinic acid prodrugs activating diverse cell-death pathways.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1028, doi. 10.1007/s10637-011-9669-6

By:

Berkovitch-Luria, Gili;
Weitman, Michal;
Nudelman, Abraham;
Rephaeli, Ada;
Malik, Zvi

Publication type:

Article

Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1116, doi. 10.1007/s10637-011-9671-z

By:

Levy, Antonin;
Albiges-Sauvin, Laurence;
Massard, Christophe;
Izzedine, Hassan;
Edhery, Stéphane;
Bahleda, Ratio;
Gomez-Roca, Carlos;
Chargari, Cyrus;
Brocheriou-Spelle, Isabelle;
Soria, Jean-Charles

Publication type:

Article

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1121, doi. 10.1007/s10637-011-9670-0

By:

Lapusan, Simona;
Vidriales, Maria;
Thomas, Xavier;
Botton, Stephane;
Vekhoff, Anne;
Tang, Ruoping;
Dumontet, Charles;
Morariu-Zamfir, Rodica;
Lambert, John;
Ozoux, Marie-Laure;
Poncelet, Philippe;
San Miguel, Jesus;
Legrand, Ollivier;
DeAngelo, Daniel;
Giles, Francis;
Marie, Jean-Pierre

Publication type:

Article

A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1203, doi. 10.1007/s10637-011-9673-x

By:

Renouf, Daniel;
Tang, Patricia;
Major, Pierre;
Krzyzanowska, Monika;
Dhesy-Thind, Bindi;
Goffin, John;
Hedley, David;
Wang, Lisa;
Doyle, L.;
Moore, Malcolm

Publication type:

Article

Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1132, doi. 10.1007/s10637-011-9674-9

By:

Okamoto, Isamu;
Yamamoto, Nobuyuki;
Kubota, Kaoru;
Ohe, Yuichiro;
Nogami, Naoyuki;
Murakami, Haruyasu;
Yamaya, Hidetoshi;
Ono, Katsuhiro;
Nakagawa, Kazuhiko

Publication type:

Article

The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1208, doi. 10.1007/s10637-011-9679-4

By:

Slingerland, Marije;
Gelderblom, Hans

Publication type:

Article

Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1211, doi. 10.1007/s10637-011-9681-x

By:

Sharma, Manish;
Wroblewski, Kristen;
Polite, Blase;
Knost, James;
Wallace, James;
Modi, Sanjiv;
Sleckman, Bethany;
Taber, David;
Vokes, Everett;
Stadler, Walter;
Kindler, Hedy

Publication type:

Article

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1216, doi. 10.1007/s10637-011-9687-4

By:

Bodoky, György;
Timcheva, Constanta;
Spigel, David;
Stella, Phillip;
Ciuleanu, Tudor;
Pover, G.;
Tebbutt, N.

Publication type:

Article